Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Executive Briefing Series (formerly The Food & Drug Letter) > ABSTRACT

Executive Briefing Series (formerly The Food & Drug Letter)

Jan. 14, 2005

ABSTRACT

Drugmakers and the FDA have faced intense scrutiny in recent months over safety concerns involving some widely marketed drugs.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives

Related Articles

Study: Teva's Copaxone the Better Treatment Option for MS FDA Work Force Needs Major Changes, Von Eschenbach Says Not All Adverse Events in Clinical Trials Should Be Reported to IRBs GSK Warns of Label Tampering on HIV Medications

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.